Acumen Pharmaceuticals, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Acumen is a clinical-stage biopharmaceutical company developing ACU193, an antibody candidate designed to target soluble amyloid-beta oligomers in early Alzheimer’s disease. The company reported no product revenue.
Key financial results
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Research and development expense | $8.7 million | $6.0 million |
| General and administrative expense | $4.4 million | $3.2 million |
| Total operating expenses | $13.1 million | $9.2 million |
| Operating loss | $13.1 million | $9.2 million |
| Interest income, net | $1.8 million | $0.1 million |
| Net loss | $11.3 million | $9.1 million |
| Net loss per share, basic and diluted | $0.28 | $0.23 |
| Net cash used in operating activities | $10.2 million | $8.3 million |
Revenue and profit margins are not meaningful for this pre-commercial company; no product sales revenue was reported. At March 31, 2023, cash and cash equivalents were $78.0 million, marketable securities were $105.8 million, and total cash and securities were $183.8 million. Working capital was $135.3 million; total liabilities were $8.8 million. The company reported no debt in the presented balance sheet.
Cash and cash equivalents declined by $52.1 million during the quarter, primarily reflecting $41.9 million of net investing outflows as the company purchased marketable securities. Operating cash use was $10.2 million. Accumulated deficit was $181.7 million.
Changes versus the prior comparable period
- Operating expenses rose 43% to $13.1 million; R&D increased 46%, mainly from clinical-trial/CRO and personnel costs, while G&A increased 37%, primarily from personnel costs.
- Net loss increased 24% to $11.3 million, despite higher interest income from the securities portfolio.
- Operating cash use increased $1.9 million. Net investing cash use increased to $41.9 million, principally due to purchases of marketable securities.
- Stock-based compensation increased to $1.4 million from $0.6 million.
Outlook, risks and other notable items
- Management expects existing cash and marketable securities to fund operating expenses and capital requirements through 2025 under its current plan. Completing a Phase 2 trial, with or without a Phase 3 expansion, will likely require additional capital to extend runway into the second half of 2026. These estimates depend on assumptions and actual cash use may be higher.
- The company expects expenses and operating losses to increase as it advances ACU193. It has not generated product revenue and may never achieve profitability; additional financing may be needed and could dilute shareholders or impose restrictive terms.
- INTERCEPT-AD, a Phase 1 trial in 65 early Alzheimer’s patients, completed enrollment in February 2023. Topline data were anticipated in the third quarter of 2023. In January, the company submitted a protocol amendment proposing a 25 mg/kg dose every two weeks for Cohort 7, down from 60 mg/kg, based partly on blinded preliminary pharmacokinetic and safety information. These preliminary observations are not definitive trial results.
- The company’s available-for-sale securities had $0.6 million of unrealized losses at quarter-end, attributed primarily to interest-rate and market-credit-spread changes; no credit losses were recognized. Management said it did not intend to sell the securities and did not expect to be required to sell before recovery of amortized cost.
- An ATM program permits up to $50 million of common-stock sales within a $200 million shelf registration; no ATM shares were sold in Q1. After quarter-end, BTIG was added as a sales agent, with commissions of up to 3% of gross proceeds.
- The company disclosed no material legal proceedings and no material changes to the risk factors in its 2022 Form 10-K. Management assessed disclosure controls as effective as of March 31, 2023.
Important facts for investors to verify
- Whether INTERCEPT-AD topline results were reported as expected and what the safety, target-engagement, and efficacy-related findings show.
- Whether ACU193’s development plan, trial timing, or dose strategy has changed following the preliminary data cited for the Cohort 7 amendment.
- Whether the projected cash runway through 2025 remains achievable, and the amount and terms of any financing needed for Phase 2 or Phase 3 development.
- How quarterly R&D spending and operating cash use evolve as clinical programs progress.
- Whether the company uses the ATM or other equity financing, and the resulting dilution to existing shareholders.